Beta Bionics, Inc. priced its initial public offering at $17.00 a share, to list on the Nasdaq Global Market. It filed a Form S-1 registration statement for an initial public offering on January 6, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, January 31, 2025).
Sell to companies like Beta Bionics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Beta Bionics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-06. It has amended it 3 times. It filed its final prospectus on 2025-01-31, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Beta Bionics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 16.6% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | 1.3% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13G, by Divisadero Street Capital Management, LP | 6.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Eventide Asset Management, LLC | 13.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 4.5% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 8.1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Levy Guy | 9.8% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 23, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 5.7% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Guy Levy | 5.8% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Hadley Harbor Aggregator IV, L.P. | — | 5%+ stakes | Source |
Check before you invest in Beta Bionics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Beta Bionics, Inc. and the records around it.
Beta Bionics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II. L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Inhibikase Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
Also filing to list on the Nasdaq Global Market
IPO filings on the Nasdaq Global Market in Q1 2025, newest first.
- Damon Inc. (Mar 2025)
Watch Beta Bionics, Inc.
Get an email when Beta Bionics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Beta Bionics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Beta Bionics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beta Bionics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 24 records.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Market (Nasdaq) under the symbol BBNX.From the 424B4 filed 2025-01-31
Shares offered
This is the initial public offering of shares of common stock of Beta Bionics, Inc. We are selling 12,000,000 shares of our common stock, and the underwriters have an option for a period of 30 days to purchase up to an additional 1,800,000 shares, consisting of 475,000 shares from us and 1,325,000 shares from the selling stockholders identified in this prospectus, in each case at the initial public offering price less the underwriting discounts and commissions.From the 424B4 filed 2025-01-31
Offering price
Gives effect to (i) the pro forma adjustments set forth in footnote (1) above and (ii) our sale of 12,000,000 shares of common stock in this offering and 1,000,000 shares in the concurrent private placement, at the initial public offering price of $17.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.From the 424B4 filed 2025-01-31
Use of proceeds
We intend to use the net proceeds from this offering and concurrent private placement, together with our existing cash, cash equivalents and short-term investments, to fund (i) the development of the bihormonal configuration of the iLet through regulatory submissions to the FDA for 510(k) clearance of the bihormonal configuration and for approval of the glucagon product;From the 424B4 filed 2025-01-31
Revenue
Our revenue for the nine months ended September 30, 2024 was $44.7 million, more than 3.5x that of our annual revenue of $12.0 million for the year ended December 31, 2023.From the S-1/A filed 2025-01-28
Net loss or income
Our net losses were $25.3 million for the nine months ended September 30, 2023 and $36.6 million for the nine months ended September 30, 2024.From the S-1/A filed 2025-01-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-06 | Registration statement filed | S-1 |
| 2025-01-22 | Registration statement amended | S-1/A |
| 2025-01-23 | Registration statement amended | S-1/A |
| 2025-01-28 | Registration statement amended | S-1/A |
| 2025-01-31 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Beta Bionics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.